---
title: "VRTX: Diversified pipeline advances with global CF launches, renal expansion, and pivotal readouts ahead"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298920359.md"
description: "The company is advancing a diversified pipeline with global launches in cystic fibrosis, expansion in renal and rare endocrine diseases, and promising assets in acute pain, diabetes, and genetic kidney disorders. Key near-term milestones include pivotal readouts for pove and inaxaplin, and continued rollout of ALYFTREK.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-09-14T12:41:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298920359.md)
  - [en](https://longbridge.com/en/news/298920359.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298920359.md)
generator: "portal-rs"
---

# VRTX: Diversified pipeline advances with global CF launches, renal expansion, and pivotal readouts ahead

The company is advancing a diversified pipeline with global launches in cystic fibrosis, expansion in renal and rare endocrine diseases, and promising assets in acute pain, diabetes, and genetic kidney disorders. Key near-term milestones include pivotal readouts for pove and inaxaplin, and continued rollout of ALYFTREK.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [VRTX.US](https://longbridge.com/en/quote/VRTX.US.md)

## Related News & Research

- [Vertex Touts Encouraging Data From 'Underappreciated' Kidney Drug](https://longbridge.com/en/news/299800601.md)
- [Vertex Pharmaceuticals Incorporated Says Inaxaplin Reduces UACR By -42.7% At Week 13 In AMKD With Modest Proteinuria](https://longbridge.com/en/news/299770014.md)
- [Vertex says Phase 2b AMPLIFIED study shows inaxaplin cuts proteinuria in APOL1-mediated kidney disease patients with modest proteinuria](https://longbridge.com/en/news/299762830.md)
- [BREAKINGVIEWS-Chinese labs are wild cards in AI governance](https://longbridge.com/en/news/300510450.md)
- [Nvidia Just Put $150 Billion Behind Its Stock. Is It Cheap Enough?](https://longbridge.com/en/news/300454444.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**